154 related articles for article (PubMed ID: 31021852)
41. Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Baxi SM; Greenblatt RM; Bacchetti P; Jin C; French AL; Keller MJ; Augenbraun MH; Gange SJ; Liu C; Mack WJ; Gandhi M;
PLoS One; 2015; 10(6):e0129100. PubMed ID: 26053176
[TBL] [Abstract][Full Text] [Related]
42. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
[TBL] [Abstract][Full Text] [Related]
43. Second-line antiretroviral therapy: long-term outcomes in South Africa.
Murphy RA; Sunpath H; Castilla C; Ebrahim S; Court R; Nguyen H; Kuritzkes D; Marconi VC; Nachega JB
J Acquir Immune Defic Syndr; 2012 Oct; 61(2):158-163. PubMed ID: 22692090
[TBL] [Abstract][Full Text] [Related]
44. Correlates of HIV detection among breastfeeding postpartum Kenyan women eligible under Option B.
Chan M; Muriuki EM; Emery S; Kanthula R; Chohan V; Frenkel LM; Wald A; Chohan B; Overbaugh J; Roxby AC
PLoS One; 2019; 14(5):e0216252. PubMed ID: 31150396
[TBL] [Abstract][Full Text] [Related]
45. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
Matthews LT; Atukunda EC; Owembabazi M; Kalyebera KP; Psaros C; Chitneni P; Hendrix CW; Marzinke MA; Anderson PL; Isehunwa OO; Hurwitz KE; Bennett K; Muyindike W; Bangsberg DR; Haberer JE; Marrazzo JM; Bwana MB
PLoS Med; 2023 Feb; 20(2):e1004088. PubMed ID: 36795763
[TBL] [Abstract][Full Text] [Related]
46. Comparing Predictive Ability of Two Objective Adherence Measures in a Community-Based Cohort on Antiretroviral Therapy in South Africa: Tenofovir Diphosphate Concentrations and Electronic Adherence Monitors.
Jennings L; Ferraris CM; Castillo-Mancilla JR; Robbins RN; Nguyen N; Leu CS; Dolezal C; Hsiao NY; Mgbako O; Joska J; Myer L; Anderson PL; Remien RH; Orrell C;
J Acquir Immune Defic Syndr; 2023 Aug; 93(4):327-332. PubMed ID: 36976520
[TBL] [Abstract][Full Text] [Related]
47. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
[TBL] [Abstract][Full Text] [Related]
48. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.
Hermans LE; Umunnakwe CN; Lalla-Edward ST; Hebel SK; Tempelman HA; Nijhuis M; Venter WDF; Wensing AMJ
Clin Infect Dis; 2023 Feb; 76(3):e553-e560. PubMed ID: 36136811
[TBL] [Abstract][Full Text] [Related]
49. Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.
Gay CL; Willis SJ; Cope AB; Kuruc JD; McGee KS; Sebastian J; Crooks AM; McKellar MS; Margolis DM; Fiscus SA; Hicks CB; Ferrari G; Eron JJ;
AIDS; 2016 Nov; 30(18):2815-2822. PubMed ID: 27662549
[TBL] [Abstract][Full Text] [Related]
50. Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure.
McCluskey SM; Govender K; Adamson J; Gandhi M; Spinelli MA; Moosa MY; Muyindike W; Moodley P; Pillay M; Masette G; Sunpath H; Pillay S; Chen G; Hedt-Gauthier B; Marconi VC; Siedner MJ
AIDS; 2023 Jun; 37(7):1109-1113. PubMed ID: 36928169
[TBL] [Abstract][Full Text] [Related]
51. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal evaluation of adherence, retention, and transition patterns of adolescents living with HIV in Nigeria.
Meloni ST; Agaba P; Chang CA; Yiltok E; Oguche S; Ejeliogu E; Agbaji O; Okonkwo P; Kanki PJ
PLoS One; 2020; 15(7):e0236801. PubMed ID: 32735566
[TBL] [Abstract][Full Text] [Related]
53. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Stranix-Chibanda L; Tierney C; Sebikari D; Aizire J; Dadabhai S; Zanga A; Mukwasi-Kahari C; Vhembo T; Violari A; Theron G; Moodley D; George K; Fan B; Sommer MJ; Browning R; Mofenson LM; Shepherd J; Nelson B; Fowler MG; Siberry GK;
PLoS One; 2021; 16(2):e0246272. PubMed ID: 33544759
[TBL] [Abstract][Full Text] [Related]
54. Self-reported Antiretroviral Adherence: Association With Maternal Viral Load Suppression in Postpartum Women Living With HIV-1 From Promoting Maternal and Infant Survival Everywhere, a Randomized Controlled Trial in Sub-Saharan Africa and India.
Nevrekar N; Butler K; Shapiro DE; Atuhaire P; Taha TE; Makanani B; Chinula L; Owor M; Moodley D; Chipato T; McCarthy K; Flynn PM; Currier J; Fowler MG; Gupta A; Suryavanshi N
J Acquir Immune Defic Syndr; 2023 Jan; 92(1):76-83. PubMed ID: 36170749
[TBL] [Abstract][Full Text] [Related]
55. Urine Tenofovir Levels Strongly Correlate With Virologic Suppression in Patients With Human Immunodeficiency Virus on Tenofovir Alafenamide-Based Antiretroviral Therapy.
Johnson KA; Okochi H; Arreguin M; Watabe J; Glidden DV; Chattopadhyay A; Imbert E; Hickey MD; Gandhi M; Spinelli M
Clin Infect Dis; 2023 Mar; 76(5):930-933. PubMed ID: 36253952
[TBL] [Abstract][Full Text] [Related]
56. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate.
Li S; Jin J; Jiang Y; Shi J; Jiang X; Lin N; Ma Z
Int J Antimicrob Agents; 2023 Mar; 61(3):106726. PubMed ID: 36646229
[TBL] [Abstract][Full Text] [Related]
57. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
58. The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
Shearer K; Fox MP; Maskew M; Berhanu R; Long L; Sanne I
PLoS One; 2013; 8(8):e71719. PubMed ID: 23940782
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
60. Decreases in Self-Reported ART Adherence Predict HIV Viremia Among Pregnant and Postpartum South African Women.
Phillips TK; Wilson IB; Brittain K; Zerbe A; Mellins CA; Remien RH; Orrell C; Abrams EJ; Myer L
J Acquir Immune Defic Syndr; 2019 Mar; 80(3):247-254. PubMed ID: 30422906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
